Search clinical trials for: Dolutegravir 50mg

Total 1142 results

National Institute of Allergy and Infectious Diseases...
ViiV Healthcare; Mylan Inc.

Recruiting

Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis

HIV-associated Tuberculosis

South Africa, Thailand
MRC/UVRI and LSHTM Uganda Research Unit
Janssen Pharmaceuticals

Recruiting

Improving HIV-1 Control in Africa With Long Acting Antiretrovirals (IMPALA)

HIV-1-infection

South Africa, Kenya, Uganda
University of KwaZulu
Centre for the AIDS Programme of Research in South Africa

Recruiting

Pharmacokinetics of Twice or Once Daily DTG (50mg) in Children With HIV and TB (ORCHID)

Tuberculosis | Hiv

South Africa
The HIV Netherlands Australia Thailand Research...
Radboud University Medical Center; Bhumibol Adulyadej Hospital; Klang Hospital; Bamrasnaradura Infectious Diseases Institute and other collaborators

Recruiting

Efficacy, Safety and Pharmacokinetics of DTG With RIF

HIV/TB Coinfection

Thailand
Fundacion SEIMC-GESIDA
ViiV Healthcare

Completed

Lamivudine/Dolutegravir in Virologically Suppressed Subjects With Expected or Confirmed Resistance to Lamivudine (VOLVER)

HIV Infections

Spain
Centre for the AIDS Programme of Research in South...
Johns Hopkins University; National Institute of Allergy and Infectious Diseases... and other collaborators

Active, not recruiting

INSTI's For The Management of HIV-associated TB (INSIGHT)

HIV/AIDS | Tuberculosis, Pulmonary

South Africa
Castagna Antonella
Bristol-Myers Squibb; ViiV Healthcare

Completed

A Study of a Nucleoside Sparing Regimen in HIV-1 Infected Patients With Detectable Viremia (Dolatav)

HIV-1 Infection

Italy
IRCCS San Raffaele
Gilead Sciences

Terminated

Switch From Dual Regimens Based on Dolutegravir Plus a Reverse Transcriptase Inhibitor to E/C/F/TAF in Virologically Suppressed, HIV-1 Infected Patients (Be-OnE) (Be-OnE)

HIV-1-infection

Italy
Fundacion SEIMC-GESIDA

Active, not recruiting

Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load (MAFALDA-R)

HIV Infections | Fatty Liver Disease

Spain
Fundação Bahiana de Infectologia

Completed

Impact of a Dolutegravir-based Regimen on Early Mortality of AIDS Patients (IDEA)

Severely Immunocompromised HIV Patients

Brazil
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1)

HIV Infections

Germany, Taiwan, France, United States, Canada, Belgium, Australia, Netherlands, Spain, United Kingdom, Italy, Argentina, Russian Federation
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)

HIV Infections

Germany, Spain, United States, Canada, Taiwan, France, Italy, Argentina, United Kingdom, Russian Federation, Australia
Instituto de Investigación Sanitaria de la Fundación...

Completed

REal-Life Cohort With DOlutegravir + LAmivudina (REDOLA)

HIV-1-infection

Spain
Indiana University

Completed

PK of JULUCA in Hemodialysis

HIV/AIDS | ESRD

United States
University of Cape Town
Wellcome Trust; Medecins Sans Frontieres, Netherlands

Completed

Standard Versus Double Dose Dolutegravir in Patients With HIV-associated Tuberculosis (RADIANT-TB)

HIV Infections | Tuberculosis

South Africa
Augusta University

Completed

Contribution of Dolutegravir to Obesity and Cardiovascular Disease

Vascular Diseases | Body Weight Changes | Cardiovascular Abnormalities | HIV-1-infection | Body Fat Disorder | HIV-Associated Lipodystrophy Syndrome | Antiviral Drug Adverse Reaction | Abnormality of Adipose Tissue

United States
Kirby Institute

Active, not recruiting

Body Composition Sub-study of the D2EFT Trial

HIV Infections

Malaysia, Zimbabwe, India, South Africa, Thailand
University of Liege

Completed

Effect of Dolutegravir Intensification on HIV-1 Reservoirs (EDIT)

HIV-1-infection

Belgium
University of Cape Town
Wellcome Trust; Médecins Sans Frontières, Belgium

Completed

Tenofovir-lamivudine-dolutegravir Combination as Second-line ART: a Randomised Controlled Trial (ARTIST)

HIV Infections

South Africa
Johns Hopkins University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Rapid HIV Treatment Initiation, Access and Engagement in Care

Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

ING200336, Pharmacokinetic and Safety Study in Pregnant Women With Human Immuno Virus Infection

HIV Infections | Arthralgia | Infection, Human Immunodeficiency Virus

Spain, Russian Federation
Michael Hoelscher
Radboud University Medical Center; German Federal Ministry of Education and... and other collaborators

Completed

BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA)

Pulmonary Tuberculoses | Other Specified Pulmonary Tuberculosis

South Africa
Rhonda Brand
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Development of a Urine-Based Point-of-Care Test for Adherence to Antiretroviral Drugs (APTAMER)

HIV | Medication Adherence

United States
University of North Carolina, Chapel Hill
ViiV Healthcare

Completed

Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection (PHI-05)

HIV | Acute HIV Infection

United States
ANRS, Emerging Infectious Diseases
UNITAID; Institut de Recherche pour le Developpement

Completed

Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings (NAMSAL)

HIV-1 Infection

Cameroon
Philip Grant

Withdrawn

Effect of Reducing Nucleotide Exposure on Bone Health (ReNew) (ReNew)

HIV/AIDS | Osteopenia | HIV-1-infection

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection

HIV Infections | Infection, Human Immunodeficiency Virus

Mexico, Peru, Thailand, South Africa, Russian Federation, Argentina, Brazil
Southern Illinois Healthcare Foundation
Janssen Scientific Affairs, LLC

Completed

A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and Dolutegravir

HIV-1-infection
ViiV Healthcare
Janssen, LP

Completed

Study to Evaluate Pharmacokinetics, Safety and Tolerability of Dolutegravir and Rilpivirine (JULUCA™) 50 Milligram (mg)/25 mg Tablets in Healthy Subjects of Japanese Descent

HIV Infections

United States
Fundacion Clinic per a la Recerca Biomédica

Unknown

Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients

HIV-1-infection | Solid Organ Transplant

Spain
University of Liverpool
ViiV Healthcare; Makerere University

Completed

Safety and Pharmacokinetics of Dolutegravir in Pregnant HIV Mothers and Their Neonates: A Pilot Study (DolPHIN1)

Pregnancy | HIV

Uganda, South Africa
Blueclinical, Ltd.

Completed

Dolutegravir Plus 2 NRTIs, in Treatment-Naïve HIV-2 Infected Subjects

HIV II Infection

Portugal
Neuroscience Trials Australia
Macquarie University, Australia; Calvary Health Care Bethlehem; Westmead Hosptial and other collaborators

Completed

Safety and Tolerability of Antiretroviral (Triumeq) in Patients With Amyotrophic Lateral Sclerosis (ALS). (Lighthouse)

Amyotrophic Lateral Sclerosis

Australia
Cristina Mussini

Unknown

Evaluating Inflammatory and Immunological Changes of HIV-positive Patients Switching to DTG Dual Regimen Compared to Those Switching to a Triple Drugs Regimen (B/F/TAF)

HIV Infections
ViiV Healthcare
GlaxoSmithKline

Completed

Bioavailability Study of 10 Milligram (mg) and 5 mg Tablets Versus Conventional Tablets of Dolutegravir

HIV Infections

United States
University Hospital Virgen de las Nieves

Unknown

Real Life Study of Dolutegravir Plus Lamivudine in HIV-1-Infected Treatment-Naive Patients (DOLAVI)

HIV-1-infection

Spain
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Drug Interaction Study Between GSK1349572 and Tipranavir/Ritonavir in Healthy Volunteers (ING)

HIV Infections | Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare

Completed

Phase 4 Study of Dolutegravir (DTG) in Russian Federation

HIV Infections | Infection, Human Immunodeficiency Virus

Russian Federation
Centre Hospitalier Régional d'Orléans

Terminated

Study to Evaluate the Efficacy of MONotherapy of TiviCAY® Versus a Triple Therapy in HIV-1-infected Patients (MONCAY)

HIV

France
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily (SPRING-2)

Infection, Human Immunodeficiency Virus I

Germany, Spain, France, Australia, United States, Canada, United Kingdom, Italy, Russian Federation
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir (VIKING-4)

HIV Infections

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)

Infection, Human Immunodeficiency Virus I

United States, Spain, Germany, Australia, Canada, Belgium, Denmark, Netherlands, United Kingdom, France, Italy, Romania
ViiV Healthcare
GlaxoSmithKline

Completed

Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects (FLAMINGO)

Infection, Human Immunodeficiency Virus

Spain, France, Germany, United States, Italy, Romania, Russian Federation, Switzerland, Puerto Rico
ViiV Healthcare
GlaxoSmithKline

Completed

Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations

Infection, Human Immunodeficiency Virus

United States
University of Liverpool
ViiV Healthcare; Makerere University

Completed

Dolutegravir Interactions With Artemisinin-based Combination Therapies (DolACT)

HIV | Malaria

Uganda
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
Andrew Carr
ViiV Healthcare Australia Pty. Ltd

Completed

The Tolerability of, and Adherence to, Dolutegravir With Co-formulated Tenofovir-emtricitabine for HIV Non-occupational Post-exposure Prophylaxis (dPEP)

Human Immunodeficiency Virus

Australia
Fundación FLS de Lucha Contra el Sida, las Enfermedades...

Completed

Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Protease Inhibitors To Dolutegravir In HIV-1-Infected Subjects With Low Bone Mineral Density

HIV-1 Infection

Spain
ViiV Healthcare
GlaxoSmithKline

Completed

Effect of Dolutegravir on Metformin Pharmacokinetics in Healthy Adult Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

A Study to Evaluate the Effects of Calcium Carbonate and Ferrous Fumarate on Pharmacokinetics of Dolutegravir in Healthy Adult Subjects

Infection, Human Immunodeficiency Virus

Search clinical trials for: Dolutegravir 50mg

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Norway

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations